(Corrects spelling of Repatha in paragraph 1)
By Jan Wolfe
Feb 25 (Reuters) - A U.S. jury on Monday said patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.
Sanofi and Regeneron had stipulated that if the Amgen patents were valid their jointly developed cholesterol drug Praluent infringed them.
Reporting by Jan Wolfe; Editing by Cynthia Osterman